Skip to main content
. 2020 Jul 29;7(17):2000411. doi: 10.1002/advs.202000411

Figure 5.

Figure 5

Antitumor immune responses in single 4T1 tumor‐bearing mice model. a) Treatment schedule for Apt/PDGs^s@pMOF‐mediated therapy. b) Tumor volume change and c) body weight change of 4T1 breast tumor‐bearing mice with different treatments. Data are presented as means ± SD (n = 5). d–f) CD3+ T cells, active CTLs, and Th1 cells levels in tumor lesions after various treatments, analyzed by flow cytometry (n = 3). g) MDSC levels in tumor lesions, analyzed by flow cytometry (n = 3). h) Matured DC levels in TDLN. i) CLSM examination of CRT exposure in different treated groups. Scale bar: 50 µm. j) Representative image increased M1 macrophages (stained with CD16/32) and declined M2 macrophages (stained with CD206). Scale bar: 50 µm. k) CLSM image of PD‐L1 expression. Scale bar: 50 µm. G1: Control + L (laser irradiation), G2: Apt/PDs^s@pMOF + L, G3: Apt/PDG@pMOF + L, G4: cApt/PDGs^s@pMOF + L, G5: Apt/PDGs^s@pMOF + L, G6: gemcitabine + L, G7: Apt/PDGs^s@pMOF + D (dark). Significance is defined as ns, no significance, * p < 0.05, ** p < 0.01, *** p < 0.001.